Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heavy metal containing doai
Patent
1992-08-11
1995-03-28
Springer, David B.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heavy metal containing doai
514186, 548104, 556133, C07C 306, A61K 31315
Patent
active
054017700
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to an antipruritic agent and an antipruritic compound, and more specifically, it relates to an antipruritic agent and an antipruritic compound, in which zinc is the main ingredient.
BACKGROUND ART
The skin possesses the function of protecting the body from various forms of stress due to the external environment, but if this body maintenance function becomes unbalanced, various forms of skin conditions appear, such as chapped skin and scabies.
As the majority of these skin conditions are accompanied by itching, this itching leads to skin pruritis, which can frequently exacerbate the original skin condition.
There are individual differences in the degree of itching in such cases of pruritic skin diseases and cases of skin pruritis, ranging from that which is extremely mild to that which is extremely severe. In addition, as a sebum deficiency, which is one cause of pruritis, is observed to some degree in the case of elderly subjects, there are cases in which urea ointment and zinc oxide ointment, etc. are used because of the moisture effects thereof.
Moreover, steroid preparations, anti-histamines and Crotamiton preparations, etc., have been widely used in the past as antipruritics.
Nevertheless, itching accompanying liver and renal disfunction and malignant tumors, metabolic disorders and senile pruritis, and pruritic skin diseases such as atopic dermatitis, eczema and urticaria, against which these antipruritics are unable to demonstrate antipruritic effects, are becoming a serious problem in the clinical setting.
As these diseases are frequently accompanied by serious itching, the particular condition may be exacerbated due to scratch to the skin resulting from that itching. As such, an antipruritic able to demonstrate adequate antipruritic effects has been long awaited. Furthermore, steroid preparations, antihistamines, and so on may cause problems due to adverse side effects, in certain cases.
DISCLOSURE OF THE INVENTION
Accordingly, the object of the present is to eliminate the above-mentioned problems of the prior art by providing an antipruritic agent and antipruritic compound free of adverse side effects, acting directly on the itching itself, and being fast-acting.
In accordance with the present invention, there is provided an antipruritic comprising a zinc-amino acid complex.
In accordance with the present invention, there is also provided an antipruritic compound comprising an antipruritic agent comprised of a zinc-amino acid complex at a concentration of 2.6.times.10.sup.-3 -2.6.times.10.sup.-1 M (molar concentration, moles/liter), and a pharmacologically acceptable carrier.
BEST MODE OF CARRYING OUT THE INVENTION
As a result of intensive research by the inventors of the present invention, to achieve the above-mentioned object, it was discovered that an antipruritic agent having superior antipruritic properties and superior useability could be obtained by bonding zinc and an amino acid in a specific proportion, which led to the completion of the present invention.
Thus, it has been reported that itching receptors exist between the epidermis and dermis layers of the skin ("Modern Medicine", Vol. 16, No. 11, pp. 46-47, 1987, Asahi Shimbunsha), and that the skin contains a high content of zinc, containing roughly 20% of the total amount of zinc in the body, with particularly large amounts contained in the epidermis ("Zinc and Clinical Medicine", Asakura Shoten, pp. 20-21, p. 123, 1984), indicating that there is an intimate relationship between the skin and zinc metabolism. In addition, a characteristic systemic skin rash occurs in hereditary Acrodermatitis entheropathica, which is primarily caused by zinc deficiency, and a long-term implementation of high-calorie infusions (venous feeding). The cause of this in the former case is an insufficient absorption of zinc in the small intestine, while the cause in the latter case is the chelation of zinc in the body by amino acids and sugars contained in the infusion liquid resulting in transport and e
REFERENCES:
patent: 4053630 (1977-10-01), Yu et al.
patent: 4089954 (1978-05-01), Morelle et al.
patent: 4112954 (1978-11-01), Morelle et al.
patent: 4652445 (1987-03-01), Ort
patent: 4711780 (1987-12-01), Fahim
patent: 4937234 (1990-06-01), Fahim
patent: 5166149 (1992-11-01), Loev
Inokuchi Miwako
Inomata Mie
Naito Yasuo
Nakajima Noriko
Taguchi Shigeru
Shiseido Company Ltd.
Springer David B.
LandOfFree
Antipruritic agents and antipruritic compositions thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antipruritic agents and antipruritic compositions thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antipruritic agents and antipruritic compositions thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2250922